ORIGIN stands for "Outcome Reduction with Initial Glargine Intervention"
What is the ORIGIN Study?
ORIGIN is an international study looking at people who are at high risk for cardiovascular disease and who also have Type 2 Diabetes or a pre-diabetic condition such as Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT). In this study attempts will be made to reduce the risk of heart attacks, strokes, and other cardiovascular events by using insulin glargine to normalize blood sugar levels. The ORIGIN study is also investigating whether or not omega-3 polyunsaturated fatty acids (n-3 PUFA) can also reduce risk. It is anticipated that 10,000 participants from all over the world will be enrolled in the ORIGIN study.
What is Insulin glargine?
Insulin glargine (also called Lantus) is a new basal insulin analogue whose slow and steady absorption allows for better blood sugar control with less hypoglycemia. Learn more about insulin analogues.
What are omega-3 polyunsaturated fatty acids?
Omega-3 polyunsaturated fatty acids are the fats present in fish oil. There has been epidemiological evidence suggesting that their consumption may reduce the risk of cardiovascular disease, but this has yet to be confirmed in a large randomized clinical trial such as ORIGIN.
What are the benefits of joining ORIGIN?
Am I eligible?
Men and women over the age of 50 are eligible for ORIGIN. You must also be willing to do finger-stick blood sugar checks and take insulin to control blood sugars. More complex eligibility criteria is listed below, but it is best to go through it with either your family doctor or you can also inquire about your eligibility by phoning the number listed below.
I am interested in volunteering or finding out more...
Hamilton General Hospital ORIGIN Clinic Phone: 905-521-2100 x44612
ORIGIN Complete Eligibility Criteria
ORIGIN Exclusion Criteria